Secondary prevention of coronary heart disease in South Wales: a survey following myocardial infarction

P M Underwood, L S Cozma, K Laji, H Cohen, K Oboubie, P Beck


Coronary heart disease (CHD) remains a major cause of morbidity and mortality in the UK. Following a myocardial infarction (MI) the risk of disease progression is high. Modification of vascular risk factors in such patients—secondary prevention—is particularly effective with evidence supporting use of antiplatelet agents, oral anticoagulants, β blockers, angiotensin converting enzyme (ACE) inhibitors, statins, and smoking cessation. Good diabetic control and provision of cardiac rehabilitation are also important.

The aim of this study was to assess the level of secondary prevention for CHD. We based the current survey on the experience we had with a previous smaller audit conducted between 1998–99.

METHODS

The audit departments from the University Hospital of Wales in Cardiff, Llandough Hospital, Cardiff, Royal Gwent Hospital, Newport, and Prince Charles Hospital Merthyr Tydfil, assisted in our survey; each generated a list of patients discharged between 1 January and 31 December 1999 following a new MI (International classification of diseases, 10th revision (ICD-10) codes 121.0–121.4, 121.9, 122.0, 122.1, 122.8, 122.9). One hundred patients were randomly selected from each hospital. Pro-formas modified from our previous audit were completed to assess CHD secondary prevention. Each set of medical and nursing records was assessed independently by two specialist registrars. Pro-formas were then compared, differences discussed and, with further reference to the case notes, resolved.

Questionnaires (maximum of two) were then sent to surviving patients requesting a current medication list, details of aspirin use, smoking status, and involvement in coronary rehabilitation.

All data were made anonymous and entered into a computer database. Statistical analysis and randomisation was performed using SPSS version 7.5.

RESULTS

Three hundred and fifty six (89%) patient records were examined. Of these 57 were found to be unsuitable (incorrectly coded or died during admission), leaving 299 records for further analysis. Mean age was 67.2 years, 71% male, mean inpatient stay 9.4 days; 44% of patients had previous vascular disease with 20% having had at least one previous MI. According to the ECGs, 40% were inferior wall MIs, 34% anterior, 3% posterior, 4% left bundle branch block, and 19% indeterminate. Two hundred and seven patients were followed up at a mean of 20 months post-discharge (86% response rate). Fifty eight unsuitable patients (deceased, living outside the area or with dementia) were not sent questionnaires.

Taking contraindications into consideration, appropriate aspirin use was 98% from discharge to follow up. At discharge β blockers were prescribed or contraindicated in 94% with 80% β blocker continuation at follow up. Heart failure was demonstrable in 187 (63%) patients, 124 (66%) of whom were on ACE inhibitors (or angiotensin II blockers) at discharge (78% appropriate use given contraindications in 23 patients). There was a marginally significant increase in total ACE inhibitor prescribing between discharge and follow up (53% to 57%, p = 0.043, Wilcoxon signed rank test), but no significant increase in prescribing or dose escalation in the cohort with left ventricular failure (LVF).

Lipids were measured in 272 (91%) patients, 86% within 24 hours of admission. Mean total cholesterol (TC) was 5.70 mmol/l; ≥ 5.0 mmol/l in 198 (66%) patients. By all criteria (TC assayed and management of high results) statin use was appropriate in 235 (79%) patients. Mean statin doses at discharge were 18, 16, and 24 mg for simvastatin, atorvastatin, and pravastatin, respectively. There was no significant change in statin prescription rates or dose titration between discharge and follow up.

At the time of MI 46% of patients were smokers and 65% had documented evidence of advice to quit. At follow up 88% of patients recalled being given advice to stop smoking and 55% indicated they had quit. Forty (13%) patients were known to have diabetes mellitus (DM). In those with unknown DM status, admission blood glucose was < 11.1 mmol/l in 205 (69%) patients, but not measured in 33 (11%) patients. Where blood glucose was high, 10 (3.3%) patients had no further assessment and 11 (3.7%) patients had a fasting blood glucose concentration; five patients were in the diabetic range and six were normal. Two hundred and ninety seven (99%) patients had pre-discharge blood pressures recorded; 260 (87%) averaged < 140/80 mm Hg. The 37 (12%) patients with persisting hypertension were on more antihypertensive drugs at discharge than admission (1.37 ± 0.97, p < 0.001, Wilcoxon signed rank test), with a further increase at follow up (1.96 ± 1.57, p = 0.007).

From the 183 replies, 138 (66%) patients recalled being offered cardiac rehabilitation sessions.

DISCUSSION

Continuing widespread under use of effective treatments was the conclusion when CHD secondary prevention was last assessed in the EuroAspire II study. Our survey does not support these findings. We have found that post-MI, many patients are receiving appropriate advice and secondary prevention.

As in our previous survey we demonstrate failure to upwardly titrate ACE inhibitor doses. Many patients with LVF remained on doses lower than those used in heart failure trials. With evidence favouring early (0–36 hours) ACE inhibition post-MI, use of dose titration packs, and our

Abbreviations: ACE, angiotensin converting enzyme; CHD, coronary heart disease; DM, diabetes mellitus; LVF, left ventricular failure; MI, myocardial infarction; TC, total cholesterol
average nine day hospital stay, this situation should be remediable.

Patients with DM have twice the risk of further MI and three times the risk of cardiovascular death of non-diabetic patients. We found 3% of patients with a possible new diagnosis of DM missed, and a further 11% with no blood glucose measurements; laboratory blood glucose should be assayed in all patients at admission and scrutinised as for lipids. Further assessment, either by fasting glucose or oral glucose tolerance testing, should be undertaken whenever doubt remains.

Our survey does suffer methodological problems. Quality data depend upon accurate case notes and in the case of questionnaires on respondent honesty, question interpretation, and memory of events (as much as two years previous in our survey). The discrepancy between documented and recalled smoking cessation advice emphasises the importance of good record keeping. A further weakness is our lack of data from EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II, Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–72.

In spite of minor differences in age range and organisation of care, the provision of secondary prevention did not notably differ across the four acute hospitals. We believe further improvements will require a more individual approach with treatment optimised according to the needs and beliefs of each patient. Studies assessing understanding and attitude post-MI demonstrate important changes with time.

Although initially enthusiastic, those with slow or incomplete recovery become despondent, and patients who recover quickly may subsequently dismiss risks as unimportant. Although the National Service Framework on CHD has afforded us an opportunity to improve the national CHD burden, the greater challenge of maximising individual benefit is yet to be fully realised.

---

### Table 1  Aspirin, β blocker, ACE inhibitor and statin use

<table>
<thead>
<tr>
<th></th>
<th>Antiplatelet or warfarin</th>
<th>ACE inhibitor or angiotensin II blocker</th>
<th>Statin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aspirin</td>
<td>Any</td>
<td>β Blocker</td>
</tr>
<tr>
<td>At admission</td>
<td></td>
<td>All patients</td>
<td>Patients with LVF</td>
</tr>
<tr>
<td>Taking drug</td>
<td>82 (27%)</td>
<td>99 (33%)</td>
<td>52 (17%)</td>
</tr>
<tr>
<td>ACE-I dose*</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Taking drug</td>
<td>255 (85%)†</td>
<td>286 (96%)†</td>
<td>180 (60%)†</td>
</tr>
<tr>
<td>Valid exclusion</td>
<td>38 (13%)</td>
<td>102 (34%)</td>
<td>–</td>
</tr>
<tr>
<td>ACE-I dose*</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>% appropriate use</td>
<td>97–100‡</td>
<td>92–96‡</td>
<td>76–88‡</td>
</tr>
</tbody>
</table>

At discharge:

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>Patients with LVF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taking drug</td>
<td>167 (81%)†</td>
<td>199 (96%)</td>
</tr>
<tr>
<td>Valid exclusion</td>
<td>38 (13%)</td>
<td>102 (34%)</td>
</tr>
<tr>
<td>% appropriate use</td>
<td>97–100‡</td>
<td>92–96‡</td>
</tr>
</tbody>
</table>

At follow up:

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>Patients with LVF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taking drug</td>
<td>119 (57%)‡</td>
<td>84 (67%)‡</td>
</tr>
<tr>
<td>Stopped taking drug</td>
<td>6 (3%)</td>
<td>12 (12%)</td>
</tr>
<tr>
<td>Started</td>
<td>6 (3%)</td>
<td>17 (17%)</td>
</tr>
<tr>
<td>ACE-I dose*</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

* Mean dose expressed as % maximum British National Formulary recommended; † p<0.001; ‡ not significant; †† p<0.05 (Kruskal–Wallis test); ††† p<0.05 (Wilcoxon signed rank test statistic for admission to discharge and discharge to follow up).

ACE-I, angiotensin converting enzyme inhibitor; LVF, left ventricular failure.

---

**Authors’ affiliations**

P M Underwood, L S Cozma, K Lai, H Cohen, K Oboubie, P Beck, University Hospital of Wales, Cardiff, UK

Correspondence to: Dr Paul M Underwood, University Hospital Wales, Cardiff CF7 2XR, UK; paul@penarthhaven.freeserve.co.uk

Accepted 16 February 2004

---

**REFERENCES**


Secondary prevention of coronary heart disease in South Wales: a survey following myocardial infarction

P M Underwood, L S Cozma, K Laji, H Cohen, K Oboubie and P Beck

*Heart* 2004 90: 1332-1333
doi: 10.1136/hrt.2003.010942

Updated information and services can be found at:
[http://heart.bmj.com/content/90/11/1332](http://heart.bmj.com/content/90/11/1332)

These include:

**References**

This article cites 4 articles, 2 of which you can access for free at:
[http://heart.bmj.com/content/90/11/1332#BIBL](http://heart.bmj.com/content/90/11/1332#BIBL)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Acute coronary syndromes (2742)
- Epidemiology (3752)
- Tobacco use (635)
- Diabetes (842)
- Metabolic disorders (1030)
- Smoking cessation (58)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)